Skip to content

News

Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development Aptamer Group signs material agreement with genetic medicines company Aptamer Group win four new contracts Aptamer Group and Neuro-Bio partner to develop an Alzheimer’s disease diagnostic test Aptamer Group consortium awarded Eurostars grant to develop a novel prenatal disease diagnostic device Launch of Optimer®-Fc as a new reagent solution for immunohistochemistry Appointment of Chief Financial Officer Aptamer Group partner with BaseCure Therapeutics to develop new targeted gene therapies Aptamer Group signs two substantial new contracts Appointment of Interim Chief Commercial Officer Aptamer Group announce new deals to support novel therapies and improved assays Baroness Greenfield opens Aptamer Group’s new state-of-the-art laboratories Aptamer Group enters next stage of development within York Science Park Aptamer Group signs deal with Flip Gene Therapeutics to support the development of inducible gene therapies Aptamer Group and PinotBio extend collaboration for the development of Optimer-drug conjugates Honorary Professorship for Aptamer Group CEO Optimer-enabled wastewater monitoring system installed in UK networks Optimer® diagnostic reagent detects omicron variant Aptamer Group and ValitaCell to develop biomanufacturing screening platform Aptamer Group and DeepVerge expand partnership for Optimer-enabled wastewater monitoring Aptamer Group signs material commercial agreement with a life science research company Aptamer Group and BizCom announce collaboration for Optimer distribution and marketing services in Japan Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests Aptamer Group signs large commercial agreement with a public life science research company Aptamer Group and WuXi AppTec Research Service Division collaborate to identify new Optimer enabled therapeutics Aptamer Group partners with top five global pharmaceutical company to support innovative vaccine development Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology Aptamer Group extends collaboration with leading biopharmaceutical company to explore next-generation drug delivery approaches Aptamer Group makes progress in 2020 Aptamer Group advances COVID-19 testing capabilities with Integumen MP praises Aptamer Group’s COVID-19 work Aptamer Group attracts top talent to its scientific team Aptamer Group and Cytiva form new collaboration for the development of COVID-19 Rapid Test Integumen signs MTA with Aptamer Group Ltd Aptamer Group making headlines on their Point of Care COVID-19 reagent developments Aptamer Group and Valitacell announce partnership to build new drug discovery platform Aptamer Group and Cancer Research UK announce partnership for drug development programme Aptamer Group Announces Agreement with AstraZeneca to Explore Next-Generation Drug Delivery Devices Expansion plans to support Aptamer Group growth Aptamer Group Secures $2.2m Series A Investment

Start your next project with Aptamer Group

Contact one of our experts today